Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Cancer chemo-immunotherapy: time will tell.

Cancer immunology research·2026
Same author

Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply.

JAMA oncology·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026
Same author

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

Journal of gynecologic oncology·2026
Same author

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).

Cancer·2026
Same journal

Design of Trials with Composite Endpoints with the R Package CompAREdesign.

Statistics in biosciences·2026
Same journal

Pan-Cancer Drug Response Prediction Using Integrative Principal Component Regression.

Statistics in biosciences·2026
Same journal

Variance Estimation for Weighted Average Treatment Effects.

Statistics in biosciences·2026
Same journal

Bayesian Modeling on Microbiome Data Analysis: Application to Subgingival Microbiome Study.

Statistics in biosciences·2026
Same journal

Canopy2: Tumor Phylogeny Inference by Bulk DNA and Single-Cell RNA Sequencing.

Statistics in biosciences·2026
Same journal

Multilevel Multivariate Functional Principal Component Analysis of Evoked and Induced Event-Related Spectral Perturbations.

Statistics in biosciences·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

A Gaussian Copula Model for Multivariate Survival Data.

Megan Othus1, Yi Li

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA 98109, Tel.: 206-667-5749.

Statistics in Biosciences
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

This study introduces a Gaussian copula model for analyzing multivariate survival data, enabling the assessment of association parameters and the incorporation of cluster effects. The method was successfully applied to a leukemia study, estimating treatment effects and institutional clustering.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 26, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

  • Biostatistics
  • Survival Analysis
  • Statistical Modeling

Background:

  • Multivariate survival data presents analytical challenges, particularly in accounting for dependencies between event times.
  • Gaussian copula models offer a flexible framework for modeling such dependencies.

Purpose of the Study:

  • To develop and validate a Gaussian copula model for multivariate survival times.
  • To enable estimation and testing of the association parameter in survival data.
  • To extend the model for cluster-level frailty and apply it to a real-world clinical dataset.

Main Methods:

  • A two-stage estimation procedure for the Gaussian copula association parameter.
  • Testing the null hypothesis of no association (parameter equals zero).
  • Extension to incorporate cluster-level frailty terms when association is positive.

Main Results:

  • The two-stage estimation procedure is easily implemented with existing software.
  • Asymptotic properties of the estimation scheme were derived.
  • Simulation studies confirmed the finite sample utility of the proposed method.
  • Application to a leukemia dataset successfully estimated marginal treatment effects and examined institutional clustering.

Conclusions:

  • The Gaussian copula model provides a robust framework for multivariate survival analysis.
  • The proposed estimation method is practical and statistically sound.
  • The model is effective in analyzing complex clinical trial data, accounting for treatment effects and potential clustering.